Where Global Innovation
and Capital Meet

Page 3

Sophia Genetics secures $234m in IPO

Genomics analytics platform developer Sophia Genetics has gone public ten years after it was co-founded by researchers from EMBL, Stanford and University of Geneva

Jul 27, 2021

Caribou Biosciences careers on to public markets

UC Berkeley’s cancer therapy developer priced a $304m initial public offering at the top of its range.

Jul 23, 2021

IsoPlexis applies itself to IPO filing

Yale University is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.

Jul 23, 2021

TScan takes in $100m through IPO

Harvard spinout TScan Therapeutics has successfully listed on the Nasdaq Global Market.

Jul 19, 2021

Dynacure sets sights on $107m IPO

The IGBMC spinout was set up by Satt Conectus and is now seeking a listing in the US with a price range of $15 to $17.

Jul 15, 2021

Tenaya Therapeutics tenses for IPO

Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.

Jul 13, 2021

Icosavax initiates IPO procedure

University of Washington spinout Icosavax has filed for an initial public offering on the Nasdaq Global Select Market, with financial terms yet to be set.

Jul 8, 2021

Caribou canters towards IPO

UC Berkeley’s cell therapy developer has filed for an initial public offering.

Jul 5, 2021

Aerovate accesses public markets

Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.

Jul 1, 2021

Duolingo cues up initial public offering

CMU-founded language learning platform developer Duolingo was valued at $2.4bn as of its last funding round in November 2020.

Jun 29, 2021

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here